Fig. 6. AKT and Notch1 inhibition by VJ reduces tumor burden in AKT-overexpressing in vivo model.

a Tumors dissected and assessed from mouse xenografts of pCMV/HCT 116 or AKT/HCT 116 cells. b Tumor volumes were measured once per week for 4 weeks, and a line graph was plotted to compare tumor growth and volume (mm³) for VJ –treated pCMV/HCT 116 and AKT/HCT 116 tumors. c Tumor sections from AKT-overexpressing tumors and pCMV/HCT 116 tumors stained immunohistochemically with pAKT, NFκB (p65), Notch1, and Ki67